☆ 4.7 Meeting Abstract

SAFETY AND EFFICACY OF MK-8669 (RIDAFOROLIMUS) + MK-2206 (AKT INHIBITOR) IN PATIENTS WITH ADVANCED BREAST CANCER WITH PI3K PATHWAY DEPENDENCE

ANNALS OF ONCOLOGY (2014)

Journal

ANNALS OF ONCOLOGY

Volume 25, Issue -, Pages 25-25

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdu071.1

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Biochemistry & Molecular Biology

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

Yixuan Ma, Sina Sender, Anett Sekora, Weibo Kong, Peter Bauer, Najim Ameziane, Ruslan Al-Ali, Susann Krake, Mandy Radefeldt, Frank Ulrich Weiss, Markus M. Lerch, Alisha Parveen, Dietmar Zechner, Christian Junghanss, Hugo Murua Escobar

Summary: This study reveals the distinct antitumor effects of PI3K/AKT pathway inhibitors against PDAC cell lines. Aberrations in specific target genes, as well as KRAS and TP53 mutations, individually or together, affect the efficacy of the two PI3K/AKT pathway inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Endocrinology & Metabolism

AKT Inhibitor MK-2206 Attenuates Sepsis Acute Lung Injury (SALI) by Regulating Macrophage Polarization and Apoptosis

Zi-Yi Wang, Zhe Guo, Xue-Song Wang, Hai-Yan Liao, Feng Chen, Yu-Xin Liu, Zhong Wang

Summary: This study found that the AKT inhibitor MK-2206 may have potential therapeutic effects on sepsis acute lung injury by regulating macrophage apoptosis and polarization, consequently inhibiting macrophage pro-inflammatory response.

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS (2023)

Add to Collection

Article Cell Biology

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro

Meiling Chen, Yihang Yu, Tao Mi, Qitong Guo, Bin Xiang, Xiaomao Tian, Liming Jin, Chunlan Long, Lianju Shen, Xing Liu, Jianbo Pan, Yuanyuan Zhang, Tao Xu, Deying Zhang, Guanghui Wei

Summary: This study explores the potential mechanism of a targeted drug, MK-2206, for improving renal fibrosis. It shows that MK-2206 effectively improves the pathological structure of the kidney and inhibits epithelial-mesenchymal transition, fibroblast activation, and extracellular matrix deposition through the inhibition of the Akt/mTOR signaling pathway.

CELLS (2022)

Add to Collection

Review Oncology

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

Huayi Li, Lorenzo Prever, Emilio Hirsch, Federico Gulluni

Summary: The PI3K signaling pathway is crucial in breast cancer and inhibitors targeting this pathway show promising activity, but resistance and adverse reactions limit their efficacy. Combination therapies and identifying suitable patient subpopulations are needed to enhance therapeutic benefit.

CANCERS (2021)

Add to Collection

Article Pharmacology & Pharmacy

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells

Hai-Ling Gao, Qingbin Cui, Jing-Quan Wang, Charles R. R. Ashby Jr, Yanchun Chen, Zhi-Xin Shen, Zhe-Sheng Chen

Summary: This study found that MK-2206 significantly enhances the efficacy of ABC transporter substrates in cancer cells overexpressing ABCG2 transporter, thus overcoming multidrug resistance. The results indicate that MK-2206 reduces the IC50 values of anticancer drugs and interacts with the ABCG2 transporter through binding in the active pocket.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Drugging the PI3K/AKT/mTOR Pathway in ER plus Breast Cancer

Carla L. Alves, Henrik J. Ditzel

Summary: The PI3K/AKT/mTOR pathway plays a crucial role in estrogen receptor-positive breast cancer tumorigenesis and drug resistance, making it a highly attractive therapeutic target. Several inhibitors targeting this pathway are currently under clinical development. The recent approval of the PIK3CA isoform-specific inhibitor alpelisib and the pan-AKT inhibitor capivasertib, in combination with fulvestrant, has provided new treatment options for advanced estrogen receptor-positive breast cancer patients. However, the clinical development of multiple inhibitors and incorporating CDK4/6 inhibitors into the standard treatment has complicated the personalization of therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Pharmacology & Pharmacy

Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease

Yanhui Liu, Haobo Kong, Heping Cai, Guanru Chen, Huiying Chen, Wenyi Ruan

Summary: This paper reviews the association between the PI3K/Akt pathway and COPD, aiming to identify new therapeutic targets for clinical intervention in this disease.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

Krisida Cerma, Federico Piacentini, Luca Moscetti, Monica Barbolini, Fabio Canino, Antonio Tornincasa, Federica Caggia, Sara Cerri, Alessia Molinaro, Massimo Dominici, Claudia Omarini

Summary: Breast cancer is the most common and deadliest cancer in women, and new drugs often have limited clinical benefits. Mutations in the PI3K/AKT/mTOR pathway are frequent in breast cancer and contribute to aggressive tumor behavior and treatment resistance. Understanding the role of PI3K-mTORC1/C2 mutations in different breast cancer subtypes is crucial for improving clinical outcomes and treatment efficacy. A broad knowledge of tumor biology will be essential for personalized breast cancer therapy in the era of precision medicine.

BIOMEDICINES (2023)

Add to Collection

Article Multidisciplinary Sciences

Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma

Supharada Tessiri, Anchalee Techasen, Sarinya Kongpetch, Achira Namjan, Watcharin Loilome, Waraporn Chan-On, Raynoo Thanan, Apinya Jusakul

Summary: This study revealed the association between genetic alterations in ARID1A and the activation of the PI3K/AKT pathway in cholangiocarcinoma (CCA). It also found that CCA cells deficient in ARID1A were more sensitive to AKT inhibition.

PEERJ (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The PI3K/Akt Pathway in Meta-Inflammation

Maricedes Acosta-Martinez, Maria Zulema Cabail

Summary: Obesity is a global epidemic and a major risk factor for cardiovascular disease, stroke, and mortality. Meta-inflammation, characterized by immune cell accumulation, dysregulation of adipokine synthesis, and increased production of proinflammatory factors, is believed to contribute to obesity's negative health consequences. The crosstalk between macrophages and adipocytes and the impairment of the PI3K/Akt signaling pathway play crucial roles in the development of meta-inflammation and insulin resistance associated with obesity.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Medicine, Research & Experimental

Targeting PI3K/AKT signaling pathway in obesity

Martina S. Savova, Liliya Mihaylova, Daniel Tews, Martin Wabitsch, Milen I. Georgiev

Summary: Obesity is a growing disorder that damages patients' quality of life and increases healthcare costs. Developing safe and innovative prevention strategies and treatments for obesity is crucial. The pathophysiology of obesity is complex and involves multiple signaling pathways, including the PI3K/AKT pathway, which plays a critical role in metabolic homeostasis. Natural compounds have been shown to target the PI3K/AKT signaling pathway and have potential for managing obesity. This paper evaluates the druggability of PI3K as a target and suggests perspectives on using natural compounds to modulate the PI3K/AKT pathway for obesity management.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Add to Collection

Article Chemistry, Medicinal

Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions

Jindi Huang, Liye Chen, Jiangxia Wu, Daiqiao Ai, Ji-Quan Zhang, Tie-Gen Chen, Ling Wang

Summary: The PI3K/AKT/mTOR pathway plays a crucial role in cell proliferation, growth, differentiation, and survival. Developing novel drugs targeting this pathway is of great importance for treating various diseases.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Oncology

Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy

Parham Jabbarzadeh Kaboli, Saber Imani, Masume Jomhori, King-Hwa Ling

Summary: Breast cancer displays poor response to conventional chemotherapy due to the activation of Akt signaling, which is considered a key factor in intrinsic and acquired drug resistance. Akt signaling not only enhances multi-drug resistance, but also plays crucial roles in cellular metabolism, apoptosis, and other processes.

AMERICAN JOURNAL OF CANCER RESEARCH (2021)

Add to Collection

Article Immunology

Co-Administration of Anticancer Candidate MK-2206 Enhances the Efficacy of BCG Vaccine Against Mycobacterium tuberculosis in Mice and Guinea Pigs

Rania Bouzeyen, Saurabh Chugh, Tannu Priya Gosain, Mohamed-Ridha Barbouche, Meriam Haoues, Kanury V. S. Rao, Makram Essafi, Ramandeep Singh

Summary: This study demonstrates that enhancing the protective efficacy of M. bovis BCG in mice and guinea pig infection models by inhibiting Akt inhibitor MK-2206 promotes FOXO3 activation and BCG-induced immune responses.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

Anna Richter, Elisabeth Fischer, Clemens Holz, Julia Schulze, Sandra Lange, Anett Sekora, Gudrun Knuebel, Larissa Henze, Catrin Roolf, Hugo Murua Escobar, Christian Junghanss

Summary: The pan-AKT inhibitor MK-2206 has been shown to effectively block B-ALL cell proliferation, and its combination with the BCL-2 inhibitor venetoclax demonstrates synergistic effects, overcoming limitations in apoptosis induction.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma

M. Valery, B. Cervantesa, C. Smolenschi, A. Boileve, V. Boige, D. Malka, A. Hollebecque, M. Ducreux

Summary: This study analyzed the safety and efficacy of combining FOLFIRI and cetuximab as a treatment for metastatic squamous cell anal carcinoma (mSCAC) in patients who had previously failed on at least one line of treatment. The combination therapy showed a good disease control rate and manageable toxicity profile. Further prospective trials are needed to validate these results.

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Article Gastroenterology & Hepatology

The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients

M. Baz, V Gondran-Teiller, B. Bressac, O. Cabaret, A. Fievet, M. Dimaria, V Goldbarg, C. Colas, M. N. Bonnet-Dupeyron, J. Tinat, M. Lebrun, V Mari, J. M. Limacher, C. Corsini, E. Ginglinger, J. C. Saurin, A. Brahimi, C. Rouzier, S. Giraud, H. Schuster, A. Hollebecque, V Boige, E. Cauchin, D. Malka, O. Caron, E. Rouleau

Summary: Germline DNA alterations in BRCA2 and ATM genes are associated with pancreatic cancer risk, and their inclusion in genetic testing for PC patients is recommended pending further studies.

DIGESTIVE DISEASES AND SCIENCES (2023)

Add to Collection

Review Oncology

Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study

Veronique Debiena, Stephane Vignot, Christophe Massardb, Gabriel Maloufa, Antoine Hollebecque, Jean-Yves Scoazec, Stefan Michiels, Loic Verlingue

Summary: Systematic tumor sequencing can potentially expand therapeutic options for patients with metastatic rare cancers, as shown in the MOSCATO-01 trial. Molecular screening identified targetable molecular alterations in a significant proportion of patients, leading to improved progression-free survival and overall survival.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-Josef Kluempen, Heung-Moon Chang, Li-Tzong Chen, Josep Tabernero, Do-Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Robert S. Epstein, Abdel-Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John A. Bridgewater

Summary: In this study, 103 patients with FGFR2-altered intrahepatic cholangiocarcinoma were treated with futibatinib for a median duration of 17.1 months. The results showed that futibatinib treatment could effectively inhibit tumor growth, improve survival, and maintain quality of life for patients.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer

Yoann Pradat, Julien Viot, Andrey A. Yurchenko, Konstantin Gunbin, Luigi Cerbone, Marc Deloger, Guillaume Grisay, Loic Verlingue, Veronique Scott, Ismael Padioleau, Leonardo Panunzi, Stefan Michiels, Antoine Hollebecque, Gerome Jules-Clement, Laura Mezquita, Antoine Laine, Yohann Loriot, Benjamin Besse, Luc Friboulet, Fabrice Andre, Paul-Henry Cournede, Daniel Gautheret, Sergey I. Nikolaev

Summary: Metastatic relapse after treatment is the main cause of cancer mortality, with unknown resistance mechanisms for most treatments. To address this issue, a pan-cancer cohort (META-PRISM) of 1,031 refractory metastatic tumors was analyzed. META-PRISM tumors, especially prostate, bladder, and pancreatic types, exhibited the most transformed genomes compared to untreated tumors. Standard-of-care resistance biomarkers were identified in only 9.6% of META-PRISM tumors, indicating a lack of clinical validation for resistance mechanisms. However, investigational and hypothetical resistance mechanisms were enriched in treated patients, supporting their potential role in treatment resistance. Furthermore, molecular markers improved 6-month survival prediction, particularly for advanced breast cancer patients. The META-PRISM cohort proves valuable for studying resistance mechanisms and conducting predictive analysis in cancer.

CANCER DISCOVERY (2023)

Add to Collection

Article Oncology

Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer

Jerome Cartry, Sabrina Bedja, Alice Boileve, Jacques R. R. Mathieu, Emilie Gontran, Maxime Annereau, Bastien Job, Ali Mouawia, Pierre Mathias, Thierry De Baere, Antoine Italiano, Benjamin Besse, Isabelle Sourrouille, Maximiliano Gelli, Mohamed-Amine Bani, Peggy Dartigues, Antoine Hollebecque, Cristina Smolenschi, Michel Ducreux, David Malka, Fanny Jaulin

Summary: The study shows that PDO-based drug testing can be conducted in routine clinical practice. The chemogram could serve as a decision-making tool for clinicians to personalize patient treatment. Therefore, PDO-based functional precision oncology should be further tested in interventional trials to assess its clinical utility in patients without actionable genomic alterations or resistance to standard of care treatments.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Multidisciplinary Sciences

Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)

Karen Leroy, Clarisse Audigier Valette, Jerome Alexandre, Lise Boussemart, Jean Chiesa, Clotilde Deldycke, Carlos Gomez-Rocca, Antoine Hollebecque, Jacqueline Lehmann-Che, Antoinette Lemoine, Sandrine Mansard, Jacques Medioni, Isabelle Monnet, Samia Mourah, Thomas Pierret, Dominique Spaeth, Alexandre Civet, Sandrine Galoin, Antoine Italiano, Tomoki Yamano

Summary: This French study provides information on the real-life actionability of a CGP test based on tissue samples, and trends to confirm its utility in clinical practice across the course of the disease, particularly for patients with lung cancer and/or advanced disease.

PLOS ONE (2023)

Add to Collection

Article Oncology

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial Cancer

Francesco Facchinetti, Antoine Hollebecque, Floriane Braye, Damien Vasseur, Yoann Pradat, Rastislav Bahleda, Cedric Pobel, Ludovic Bigot, Olivier Deas, Juan DavidFlorez Arango, Giorgia Guaitoli, Hayato Mizuta, David Combarel, Lambros Tselikas, Stefan Michiels, Sergey I. Nikolaev, Jean-Yves Scoazec, Santiago Ponce-Aix, Benjamin Besse, Ken A. Olaussen, Yohann Loriot, Luc Friboulet

Summary: In this study, we identified a high frequency of FGFR kinase domain mutations responsible for resistance to FGFR inhibitors in urothelial cancer patients. Off-target resistance mechanisms mainly involved the PI3K-mTOR pathway. Our findings provide preclinical evidence supporting combinatorial treatment strategies to overcome bypass resistance.

CANCER DISCOVERY (2023)

Add to Collection

Review Oncology

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments

Marine Valery, Damien Vasseur, Francesco Fachinetti, Alice Boileve, Cristina Smolenschi, Anthony Tarabay, Leony Antoun, Audrey Perret, Alina Fuerea, Thomas Pudlarz, Valerie Boige, Antoine Hollebecque, Michel Ducreux

Summary: Biliary tract cancers are rare and often diagnosed at an advanced stage with poor prognosis. Only limited first- and second-line treatments are available, and there is a high rate of targetable somatic alterations. FDA has approved several drugs, but there are still other potentially targetable alterations that require further research.

CANCERS (2023)

Add to Collection

Meeting Abstract Oncology

Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

Yoann Pradat, Julien Viot, Konstantin Gunbin, Andrey Yurchenko, Luigi Cerbone, Marc Deloger, Guillaume Grisay, Loic Verlingue, Veronique Scott, Ismael Padioleau, Leonardo Panunzi, Stefan Michiels, Antoine Hollebecque, Gerome Jules-Clement, Laura Mezquita, Antoine Laine, Yohann Loriot, Benjamin Besse, Luc Friboulet, Fabrice Andre, Paul-Henry Cournede, Daniel Gautheret, Sergey Nikolaev

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Yonina R. Murciano-Goroff, Rebecca S. Heist, Yasutoshi Kuboki, Takafumi Koyama, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Amita Patnaik, Toshio Shimizu, Alexander I. Spira, Misako Nagasaka, Ji-Youn Han, Wade Thomas Iams, Dustin Deming, Justin Call, Philippe Cassier, Sae-Won Han, Quincy Siu-Chung Chu, Rasha Cosman, Gregory Durm, Timothy Burns, Melinda D. Willard, Shiyao Liu, Sophie Callies, Arjun V. Balar, Joshua K. Sabari

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors

Jordi Rodon, Lipika Goyal, Teresa Macarulla Mercade, Masafumi Ikeda, Shunsuke Kondo, Do-Youn Oh, Li-Yuan Bai, Makoto Ueno, Antoine Italiano, Kyriakos Papadopoulos, David Spigel, Sani H. Kizilbash, Rasha Cosman, Joon Oh Park, Li-Tzong Chen, Tomoya Yokota, Anita A. Turk, Chih-Yi Liao, Rachna Shroff, Anthony El-Khoueiry, Taroh Satoh, Antoine Hollebecque, Mitesh J. Borad, Nilofer Azad, Kurt A. Jaeckle, Herbert H. Loong, Jorge Adeva, Wei Peng Yong, Junjie Zhao, Hui Liu, Anna M. Szpurka, Ivelina Gueorguieva, Kamnesh R. Pradhan, Xiaojian Xu, James J. Harding

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

COBRA: Characteristics and Outcomes of patients with BReast cancer in phAse I trials at Gustave Roussy Cancer center

Lauren Seknazi, Arthur Geraud, Vincent Goldschmidt, Capucine Baldini, Stephane Champiat, Christophe Massard, Sophie Postel-Vinay, Aurelien Marabelle, Rastilav Bahleda, Antoine Hollebecque, Cristina Smolenschi, Anas Gazzah, Jean-Marie Michot, Patricia Martin-Romano, Aurore Vozy, Perrine Vuagnat, Francois-Xavier Danlos, Arnaud Bayle, Linda Mahjoubi, Barbara Pistilli, Yohann Loriot, Santiago Ponce-Aix, Kaissa Ouali

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Integrative pancancer genomic and transcriptomic analyses of refractory metastatic cancer

Yoann Pradat, Julien Viot, Konstantin Gunbin, Andrei Iurchenko, Marc Deloger, Luigi Cerbone, Guillaume Grisay, Loic Verlingue, Veronique Scott, Stefan Michiels, Antoine Hollebecque, Gerome Jules-Clement, Antoine Laine, Luc Friboulet, Laura Mezquita, Yohann Loriot, Benjamin Besse, Fabrice Andre, Paul-Henry Cournede, Daniel Gautheret, Sergey Nikolaev

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis.

Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do-Youn Oh, John A. Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.